Selective serotonin reuptake inhibitors and adverse pregnancy outcomes - PubMed (original) (raw)
Selective serotonin reuptake inhibitors and adverse pregnancy outcomes
Shi Wu Wen et al. Am J Obstet Gynecol. 2006 Apr.
Abstract
Objective: The purpose of this study was to assess the safety of the use of selective serotonin reuptake inhibitors in pregnancy.
Study design: We carried out a retrospective cohort study of 972 pregnant women who had been given at least 1 selective serotonin reuptake inhibitor prescription in the year before delivery and 3878 pregnant women who did not receive selective serotonin reuptake inhibitors and who were matched by the year of the infant's birth, the type of institute at birth, and the mother's postal code from 1990 to 2000 in the Canadian province of Saskatchewan.
Results: The risks of low birth weight (adjusted odds ratio, 1.58; 95% CI, 1.19, 2.11), preterm birth (adjusted odds ratio, 1.57; 95% CI, 1.28, 1.92), fetal death (adjusted odds ratio, 2.23; 95% CI, 1.01, 4.93), and seizures (adjusted odds ratio, 3.87; 95% CI, 1.00, 14.99) were increased in infants who were born to mothers who had received selective serotonin reuptake inhibitor therapy.
Conclusion: The use of selective serotonin reuptake inhibitors in pregnancy may increase the risks of low birth weight, preterm birth, fetal death, and seizures.
Comment in
- Adverse pregnancy outcomes with SSRIs.
Goldstein DJ. Goldstein DJ. Am J Obstet Gynecol. 2007 Jan;196(1):e25; author reply e25. doi: 10.1016/j.ajog.2006.06.027. Epub 2006 Jul 5. Am J Obstet Gynecol. 2007. PMID: 16824467 No abstract available. - SSRIs and adverse pregnancy outcomes.
Heres M, Honig A, Wennink H. Heres M, et al. Am J Obstet Gynecol. 2007 Jan;196(1):e26; author reply e26. doi: 10.1016/j.ajog.2006.06.025. Epub 2006 Jul 17. Am J Obstet Gynecol. 2007. PMID: 16846578 No abstract available.
Similar articles
- Maternal serotonin: implications for the use of selective serotonin reuptake inhibitors during gestation†.
Domingues RR, Wiltbank MC, Hernandez LL. Domingues RR, et al. Biol Reprod. 2023 Jul 11;109(1):17-28. doi: 10.1093/biolre/ioad046. Biol Reprod. 2023. PMID: 37098165 Free PMC article. Review. - Risks associated with selective serotonin reuptake inhibitors in pregnancy.
Malm H, Klaukka T, Neuvonen PJ. Malm H, et al. Obstet Gynecol. 2005 Dec;106(6):1289-96. doi: 10.1097/01.AOG.0000187302.61812.53. Obstet Gynecol. 2005. PMID: 16319254 - Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes.
El Marroun H, Jaddoe VW, Hudziak JJ, Roza SJ, Steegers EA, Hofman A, Verhulst FC, White TJ, Stricker BH, Tiemeier H. El Marroun H, et al. Arch Gen Psychiatry. 2012 Jul;69(7):706-14. doi: 10.1001/archgenpsychiatry.2011.2333. Arch Gen Psychiatry. 2012. PMID: 22393202 - Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors.
Grzeskowiak LE, Gilbert AL, Morrison JL. Grzeskowiak LE, et al. J Clin Psychopharmacol. 2012 Oct;32(5):615-21. doi: 10.1097/JCP.0b013e31826686bc. J Clin Psychopharmacol. 2012. PMID: 22926594 - [Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].
Favrelière S, Nourrisson A, Jaafari N, Pérault Pochat MC. Favrelière S, et al. Encephale. 2010 Jun;36 Suppl 2:D133-8. doi: 10.1016/j.encep.2009.06.005. Epub 2009 Sep 19. Encephale. 2010. PMID: 20513456 Review. French.
Cited by
- Consensus Panel Recommendations for the Pharmacological Management of Pregnant Women with Depressive Disorders.
Eleftheriou G, Zandonella Callegher R, Butera R, De Santis M, Cavaliere AF, Vecchio S, Pistelli A, Mangili G, Bondi E, Somaini L, Gallo M, Balestrieri M, Albert U. Eleftheriou G, et al. Int J Environ Res Public Health. 2023 Aug 11;20(16):6565. doi: 10.3390/ijerph20166565. Int J Environ Res Public Health. 2023. PMID: 37623151 Free PMC article. - Maternal serotonin: implications for the use of selective serotonin reuptake inhibitors during gestation†.
Domingues RR, Wiltbank MC, Hernandez LL. Domingues RR, et al. Biol Reprod. 2023 Jul 11;109(1):17-28. doi: 10.1093/biolre/ioad046. Biol Reprod. 2023. PMID: 37098165 Free PMC article. Review. - Duloxetine Exposure During Pregnancy and the Risk of Offspring Being Born Small for Gestational Age or Prematurely: A Nationwide Danish and Swedish Safety Study.
Ankarfeldt MZ, Petersen J, Andersen JT, Fernandes MFS, Li H, Motsko SP, Fast T, Jimenez-Solem E. Ankarfeldt MZ, et al. Drugs Real World Outcomes. 2023 Mar;10(1):69-81. doi: 10.1007/s40801-022-00334-2. Epub 2022 Nov 10. Drugs Real World Outcomes. 2023. PMID: 36355315 Free PMC article. - Selective Serotonin Reuptake Inhibitors (SSRIs) in Pregnancy: An Updated Review on Risks to Mother, Fetus, and Child.
Lebin LG, Novick AM. Lebin LG, et al. Curr Psychiatry Rep. 2022 Nov;24(11):687-695. doi: 10.1007/s11920-022-01372-x. Epub 2022 Oct 1. Curr Psychiatry Rep. 2022. PMID: 36181572 Free PMC article. Review. - The development of a patient decision aid to reduce decisional conflict about antidepressant use in pregnancy.
Hussain-Shamsy N, Somerton S, Stewart DE, Grigoriadis S, Metcalfe K, Oberlander TF, Schram C, Taylor VH, Dennis CL, Vigod SN. Hussain-Shamsy N, et al. BMC Med Inform Decis Mak. 2022 May 13;22(1):130. doi: 10.1186/s12911-022-01870-1. BMC Med Inform Decis Mak. 2022. PMID: 35562801 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources